1
|
Nishikawa M, Kanno H, Zhou Y, Xiao TH, Suzuki T, Ibayashi Y, Harmon J, Takizawa S, Hiramatsu K, Nitta N, Kameyama R, Peterson W, Takiguchi J, Shifat-E-Rabbi M, Zhuang Y, Yin X, Rubaiyat AHM, Deng Y, Zhang H, Miyata S, Rohde GK, Iwasaki W, Yatomi Y, Goda K. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun 2021; 12:7135. [PMID: 34887400 PMCID: PMC8660840 DOI: 10.1038/s41467-021-27378-2] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2021] [Accepted: 11/16/2021] [Indexed: 12/19/2022] Open
Abstract
A characteristic clinical feature of COVID-19 is the frequent incidence of microvascular thrombosis. In fact, COVID-19 autopsy reports have shown widespread thrombotic microangiopathy characterized by extensive diffuse microthrombi within peripheral capillaries and arterioles in lungs, hearts, and other organs, resulting in multiorgan failure. However, the underlying process of COVID-19-associated microvascular thrombosis remains elusive due to the lack of tools to statistically examine platelet aggregation (i.e., the initiation of microthrombus formation) in detail. Here we report the landscape of circulating platelet aggregates in COVID-19 obtained by massive single-cell image-based profiling and temporal monitoring of the blood of COVID-19 patients (n = 110). Surprisingly, our analysis of the big image data shows the anomalous presence of excessive platelet aggregates in nearly 90% of all COVID-19 patients. Furthermore, results indicate strong links between the concentration of platelet aggregates and the severity, mortality, respiratory condition, and vascular endothelial dysfunction level of COVID-19 patients.
Collapse
Affiliation(s)
- Masako Nishikawa
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Hiroshi Kanno
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Yuqi Zhou
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Ting-Hui Xiao
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan.
| | - Takuma Suzuki
- Department of Computational Biology and Medical Sciences, The University of Tokyo, Chiba, 277-8562, Japan
| | - Yuma Ibayashi
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Jeffrey Harmon
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Shigekazu Takizawa
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Kotaro Hiramatsu
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
- Research Center for Spectrochemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | | | - Risako Kameyama
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Walker Peterson
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Jun Takiguchi
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan
| | | | - Yan Zhuang
- Department of Electrical and Computer Engineering, University of Virginia, Virginia, 22908, USA
| | - Xuwang Yin
- Department of Electrical and Computer Engineering, University of Virginia, Virginia, 22908, USA
| | | | - Yunjie Deng
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Hongqian Zhang
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
| | - Shigeki Miyata
- Research and Development Department, Central Blood Institute, Japanese Red Cross Society, Tokyo, 135-8521, Japan
| | - Gustavo K Rohde
- Department of Biomedical Engineering, University of Virginia, Virginia, 22908, USA
- Department of Electrical and Computer Engineering, University of Virginia, Virginia, 22908, USA
| | - Wataru Iwasaki
- Department of Computational Biology and Medical Sciences, The University of Tokyo, Chiba, 277-8562, Japan
- Department of Biological Sciences, The University of Tokyo, Tokyo, 113-0033, Japan
- Department of Integrated Biosciences, The University of Tokyo, Chiba, 277-8562, Japan
| | - Yutaka Yatomi
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
| | - Keisuke Goda
- Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan.
- Institute of Technological Sciences, Wuhan University, 430072, Hubei, China.
- Department of Bioengineering, University of California, Los Angeles, California, 90095, USA.
| |
Collapse
|
2
|
Haybar H, Maleki Behzad M, Shahrabi S, Ansari N, Saki N. Expression of Blood Cells Associated CD Markers and Cardiovascular Diseases: Clinical Applications in Prognosis. Lab Med 2020; 51:122-142. [PMID: 31340048 DOI: 10.1093/labmed/lmz049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Cardiovascular diseases (CVDs) are a major cause of mortality worldwide. The results of various studies have shown that abnormality in the frequency and function of blood cells can be involved in CVD complications. In this review, we have focused on abnormalities in the expression of the CD (cluster of differentiation) markers of blood cells to assess the association of these abnormalities with CVD prognosis. METHODS We identified the relevant literature through a PubMed search (1990-2018) of English-language articles using the terms "Cardiovascular diseases", "CD markers", "leukocytes", "platelets", and "endothelial cells". RESULTS There is a variety of mechanisms for the effect of CD-marker expressions on CVDs prognosis, ranging from proinflammatory processes to dysfunctional effects in blood cells. CONCLUSION Considering the possible effects of CD-marker expression on CVDs prognosis, particularly prognosis of acute myocardial infarction and atherosclerosis, long-term studies in large cohorts are required to identify the prognostic value of CD markers and to target them with appropriate therapeutic agents.
Collapse
Affiliation(s)
- Habib Haybar
- Atherosclerosis Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Masumeh Maleki Behzad
- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Saeid Shahrabi
- Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
| | - Narges Ansari
- Isfahan Bone Metabolic Disorders Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Najmaldin Saki
- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| |
Collapse
|
4
|
Suzuki S, Kudo H, Koyama T. Assessment of spontaneous platelet aggregation using laser light scattering in healthy subjects: an attempt to standardize. Int J Lab Hematol 2014; 36:676-85. [PMID: 24661348 DOI: 10.1111/ijlh.12208] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Accepted: 02/10/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION When measuring platelet aggregation using laser light scattering, small aggregates forming without the addition of agonists may be observed. This event is called 'spontaneous platelet aggregation (SPA)'. The platelet hyperactivity observed in arterial thrombotic diseases can be detected with relative ease by measuring SPA. Standardization is urgently needed because of differences between measurement conditions among various laboratories. METHODS We conducted a systematic study of factors that affect SPA measurement, compared SPA results to flow cytometry detection of surface antigens expressed on activated platelet membranes (P-selectin, activated glycoprotein IIb/IIIa), and determined conditions that yield stable measurements. RESULTS AND CONCLUSIONS We evaluated results from 125 healthy volunteers and established conditions for a stable measurement of SPA. As the occurrence of SPA tended to increase with age, we determined conditions valid for subjects aged 20-60 years. Blood should be collected using a syringe, and the sample should be prepared after allowing the whole blood to rest for 30 min after collection. To isolate platelet-rich plasma, a 2-mL tube should be used and centrifuged at 150 g. The sample should be stored at room temperature, the platelet count of the sample should be (250 ± 10) × 10(9) /L, and the measurement should be completed within 90 min of blood collection.
Collapse
Affiliation(s)
- S Suzuki
- Laboratory Molecular Genetics of Hematology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan; Department of Clinical Laboratory Medicine, Faculty of Health Science Technology, Bunkyo Gakuin University, Bunkyo-ku, Tokyo, Japan
| | | | | |
Collapse
|